Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
about
Simplified Reversed Chloroquines To Overcome Malaria Resistance to Quinoline-Based DrugsAntimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.In vitro activity of antiretroviral drugs against Plasmodium falciparumDrugs for malaria: something old, something new, something borrowed.Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa.Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected PopulationHIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 studySaquinavir inhibits the malaria parasite's chloroquine resistance transporter.Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adultsComparative study of chloroquine and quinine on malaria rodents and their effects on the mouse testis.Asexual and sexual stages of Plasmodium falciparum in Nigerian pregnant women attending antenatal booking clinicIdentification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignanciesChloroquine-containing compounds: a patent review (2010 - 2014).Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.Lopinavir/ritonavir enhanced the antimalarial activity of amodiaquine and artesunate in a mouse model of Plasmodium berghei.Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo.HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites.Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies
P2860
Q33601788-DFCCA9AF-11C4-40AF-B90D-D54C0EEC726DQ35004887-095FE26D-BD42-48EC-909C-C6C883C086EDQ35012924-C808528C-2B53-4E77-8CDB-017CCAB5EE5AQ35363679-7D6442B2-DA4E-4F51-84EA-154B8FF7FAE3Q35507886-735D1A1D-CC11-4896-8CE3-465E8C88A47AQ35602042-7B4CF904-6E85-4C69-A976-36B53A43B59BQ35656242-AB7796A6-EC92-4D8F-8FC0-30AD6301A78FQ35689395-B8470772-041B-465A-9553-74234D0D2BE5Q35941244-4B44F889-6398-431E-9CE4-62C148829394Q36144257-D38199BC-65B2-4BA7-B069-990F62D48AECQ36719693-F17313B6-DC24-42ED-A8B0-9CA72551148EQ37185859-AAB5F28B-F0DD-4BB8-A03F-70710C571A48Q37274961-CCFF76F7-6C17-4189-A356-4B9E784C8123Q38503439-05AEA686-A75F-4F25-BD4F-D08606BA4D38Q39947285-2347510C-0B5C-4067-BBF6-44233C2D8EFAQ40782783-9E38A6BE-8BB4-45F5-8C3A-CF101A61F0F7Q41932891-3C27B76C-D09F-4EB2-835E-1A431AED3DFCQ42102873-4841DBC1-9D7A-462B-BCEE-9AB0E4379420Q56355771-AB113819-43DE-46EE-8582-F5822DDF0551
P2860
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Synergy of human immunodeficie ...... d Plasmodium chabaudi in vivo.
@ast
Synergy of human immunodeficie ...... d Plasmodium chabaudi in vivo.
@en
type
label
Synergy of human immunodeficie ...... d Plasmodium chabaudi in vivo.
@ast
Synergy of human immunodeficie ...... d Plasmodium chabaudi in vivo.
@en
prefLabel
Synergy of human immunodeficie ...... d Plasmodium chabaudi in vivo.
@ast
Synergy of human immunodeficie ...... d Plasmodium chabaudi in vivo.
@en
P2093
P2860
P921
P356
P1476
Synergy of human immunodeficie ...... d Plasmodium chabaudi in vivo.
@en
P2093
Jianlan You
Nanzheng Peng
Xiaoping Chen
Zhengxiang He
P2860
P304
P356
10.1128/AAC.01329-07
P407
P577
2008-04-28T00:00:00Z